-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 million

PUBT·07/29/2026 20:15:43
Listen to the news
Corcept Q2 FY26 net income rises to $43 million; revenue climbs 32% to $256.1 million
  • Corcept Q2 revenue rose 32% to USD 256.1 million, with Korlym and authorized generic at USD 208.6 million and Lifyorli at USD 47.6 million.
  • Net income increased to USD 43 million; diluted EPS climbed to USD 0.36.
  • Operating expenses grew to USD 214.8 million, due to spending to launch Lifyorli and investments in the Cushing’s syndrome business.
  • Over 1,300 patients have started Lifyorli since the March FDA approval, with demand accelerating each month.
  • 2026 revenue guidance increased to USD 1.1 billion-USD 1.2 billion; cash and investments totaled USD 544.6 million at June 30.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 202607291605BIZWIRE_USPR_____20260729_BW465503) on July 29, 2026, and is solely responsible for the information contained therein.